Evidence map›Paper›PMID 36074794›Full record

ArticlePLoS pathogens2022

Measuring the latent reservoir for HIV-1: Quantification bias in near full-length genome sequencing methods.

Jennifer A White, Joshua T Kufera, Niklas Bachmann, Weiwei Dai, Francesco R Simonetti, Ciara Armstrong, Jun Lai, Subul Beg, Janet D Siliciano, Robert F Siliciano

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jennifer A WhiteDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Joshua T KuferaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Niklas BachmannDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Weiwei DaiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Francesco R SimonettiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Ciara ArmstrongDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Jun LaiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Subul BegDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Janet D SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.ORCID 0000-0002-1764-1993
Johns Hopkins University · USHoward Hughes Medical Institute · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Combined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6M
Howard Hughes Medical InstituteNIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI126603NIAID NIH HHS UM1 AI126620
6 · The paper itself

Abstract

Antiretroviral therapy (ART) effectively inhibits HIV-1 replication but is not curative due to the persistence of a latent viral reservoir in resting CD4+ T cells. This reservoir is a major barrier to cure. Sequencing studies have revealed that the population of proviruses persisting in ART-treated individuals is dominated by defective proviruses that cannot give rise to viral rebound due to fatal defects including large deletions and APOBEC3-mediated hypermutation. Near full genome sequencing (nFGS) of individual proviruses is used in reservoir assays to provide an estimate of the fraction of proviruses that are intact. nFGS methods rely on a long-distance outer PCR capturing most (~9 kb) of the genome, followed by nested inner PCRs. The outer PCR is carried out at limit dilution, and interpretation of the results is based on the assumption that all proviruses are quantitatively captured. Here, we evaluate nFGS methods using the intact proviral DNA assay (IPDA), a multiplex digital droplet PCR assay that quantitates intact and defective proviruses with single molecule sensitivity using only short, highly efficient amplicons. We analyzed proviral templates of known sequence to avoid the additional complication of sequence polymorphism. With the IPDA, we quantitated molecular yields at each step of nFGS methods. We demonstrate that nFGS methods are inefficient and miss ~70% of full-length proviruses due to amplification failure at the initial outer PCR step. In contrast, proviruses with large internal deletions encompassing 70% of the genome can be quantitatively amplified under the same conditions. Accurate measurement of the latent reservoir of HIV-1 is essential for evaluating the efficacy of cure strategies, and the bias against full length proviruses in nFGS methods must be considered.

Indexed as

HIV-1HIV InfectionsHIV SeropositivityCD4-Positive T-LymphocytesDNA, ViralHumansProvirusesViral LoadDNA, Viral

Identifiers

PMID36074794
PMCPMC9488763
OpenAlexW4294990799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.